123 related articles for article (PubMed ID: 36689499)
21. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
22. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I; Ahmed T; McQuade JL; Nebhan CA; Park JJ; Versluis JM; Serra-Bellver P; Khan Y; Slattery T; Oberoi HK; Ugurel S; Haydu LE; Herbst R; Utikal J; Pföhler C; Terheyden P; Weichenthal M; Gutzmer R; Mohr P; Rai R; Smith JL; Scolyer RA; Arance AM; Pickering L; Larkin J; Lorigan P; Blank CU; Schadendorf D; Davies MA; Carlino MS; Johnson DB; Long GV; Lo SN; Menzies AM
J Clin Oncol; 2022 Apr; 40(10):1068-1080. PubMed ID: 35143285
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P; Ahmed T; Lo SN; Shoushtari A; Zaremba A; Versluis JM; Mangana J; Weichenthal M; Si L; Lesimple T; Robert C; Trojanello C; Wicky A; Heywood R; Tran L; Batty K; Dimitriou F; Stansfeld A; Allayous C; Schwarze JK; Mooradian MJ; Klein O; Mehmi I; Roberts-Thomson R; Maurichi A; Yeoh HL; Khattak A; Zimmer L; Blank CU; Ramelyte E; Kähler KC; Roy S; Ascierto PA; Michielin O; Lorigan PC; Johnson DB; Plummer R; Lebbe C; Neyns B; Sullivan R; Hamid O; Santinami M; McArthur GA; Haydon AM; Long GV; Menzies AM; Carlino MS
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793872
[TBL] [Abstract][Full Text] [Related]
24. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
26. Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma.
Jan Willem Rauwerdink D; van Persijn van Meerten E; van der Hage J; Kapiteijn E
Melanoma Res; 2022 Feb; 32(1):45-54. PubMed ID: 34725314
[TBL] [Abstract][Full Text] [Related]
27. Hyperprogression in advanced melanoma is not restricted to immunotherapy.
Fournier M; Mortier L; Dereure O; Dalac S; Oriano B; Dalle S; Lebbé C
Eur J Cancer; 2023 Nov; 193():113289. PubMed ID: 37690179
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
29. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.
Hao M; Zhao G; Du X; Yang Y; Yang J
Tumour Biol; 2016 Aug; 37(8):10339-48. PubMed ID: 26846098
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.
Mori T; Namikawa K; Yamazaki N; Kiniwa Y; Yamasaki O; Yoshikawa S; Inozume T; Kato H; Nakai Y; Fukushima S; Takenouchi T; Maekawa T; Matsushita S; Otsuka A; Nomura M; Baba N; Isei T; Saito S; Fujimoto N; Tanaka R; Kaneko T; Kuwatsuka Y; Matsuya T; Nagase K; Onishi M; Onuma T; Nakamura Y
Front Med (Lausanne); 2023; 10():1229937. PubMed ID: 37636577
[TBL] [Abstract][Full Text] [Related]
32. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.
Zheng Q; Li J; Zhang H; Wang Y; Zhang S
Front Oncol; 2020; 10():602705. PubMed ID: 33344255
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody.
Lee J; Lee SJ; Kim K; Kim ST; Jang KT; Lee J
BMC Cancer; 2019 Aug; 19(1):805. PubMed ID: 31412814
[TBL] [Abstract][Full Text] [Related]
35. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
36. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
37. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
38. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
Wei X; Wu D; Chen Y; Li H; Zhang R; Yao H; Chi Z; Cui C; Bai X; Mao L; Qi Z; Li K; Lan S; Chen L; Guo R; Yao X; Lian B; Kong Y; Dai J; Tang B; Wang X; Guo J; Si L
Br J Dermatol; 2022 Jun; 186(6):977-987. PubMed ID: 35042273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
